Zegerid study finds acid control edge
This article was originally published in The Tan Sheet
Executive Summary
Merck Consumer Care's proton pump inhibitor Zegerid OTC (omeprazole/sodium bicarbonate) is clinically shown to offer "greater and faster acid control" after seven days of treatment than Prevacid 24HR (lansoprazole), Merck says. However, this does not translate to faster heartburn symptom relief than Novartis' PPI, Merck added in a May 4 release. Despite being the only dual-ingredient OTC PPI on the market, Zegerid OTC does not tout clinical superiority over Prevacid 24HR or Procter & Gamble's Prilosec OTC (omeprazole) (1"The Tan Sheet" Dec. 7, 2009). Merck declined to comment on whether it will use the study results in labeling or marketing
You may also be interested in...
Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now
Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.